Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06633965 · ClinicalTrials.gov registry record · NA
Safety and Feasibility Testing of a Smaller Network Version of AIDANET
A NA study, sponsored by Marc Breton.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT06633965: Completed NA study, sponsored by Marc Breton.
NCT06633965 is a NA study that has completed, run by Marc Breton. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06633965, a NA study, has completed, sponsored by Marc Breton.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
A randomized 1:1 crossover trial that intends to demonstrate feasibility and safety of the Automated Insulin Delivery as Adaptive NETwork (AIDANET) system run in a new smaller network version, used in full closed loop (FCL) by adults who have been diagnosed with type 1 diabetes (T1D).
Primary Outcome
This study represents a small pilot study to assess the safety and efficacy of the small-version AIDANET system and is not formally powered. Nevertheless, the randomized crossover design will allow for analysis of period effects between Group A and Group B. Comparison between these groups will be made to determine if a period effect can explain part of the benefit of the FCL system during the at-home period.
Interventions
- DEVICE AIDANET
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-11-20 |
| Est. Completion | 2024-12-18 |
| Phase | NA |
What the finished NCT06633965 record still lists
NCT06633965 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which AIDANET is the first listed.
NCT06633965 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06633965 about?
NCT06633965 is a clinical study titled "Safety and Feasibility Testing of a Smaller Network Version of AIDANET". A randomized 1:1 crossover trial that intends to demonstrate feasibility and safety of the Automated Insulin Delivery as Adaptive NETwork (AIDANET) system run in a new smaller network version, used in full closed loop (FCL) by adults who have been diagnosed with type 1 diabetes (T1D).
What is the current status of trial NCT06633965?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2024-11-20. Estimated completion is 2024-12-18.
What interventions are being tested in trial NCT06633965?
The interventions under investigation include: AIDANET (DEVICE).
Who is sponsoring clinical trial NCT06633965?
This trial is sponsored by Marc Breton, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06633965's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI